BetterLife Pharma Appoints Former NHL Player Daniel Carcillo as Corporate Advisor to Advance Non-Hallucinogenic LSD Derivative Development
TL;DR
BetterLife Pharma gains competitive advantage by hiring former NHL champion Daniel Carcillo to advance their non-hallucinogenic LSD derivative BETR-001 for traumatic brain injury treatment.
BetterLife's BETR-001 is a non-controlled LSD derivative in preclinical development that can be self-administered for neurological disorders with patent protection until approximately 2042.
This development offers hope for athletes, veterans, and concussion survivors to heal from traumatic brain injuries and regain their quality of life through accessible treatment.
A two-time Stanley Cup champion forced to retire from concussions now advises a biotech company developing a non-hallucinogenic LSD derivative to treat brain injuries.
Found this article helpful?
Share it with your network and spread the knowledge!
BetterLife Pharma Inc. has announced the appointment of Daniel Carcillo as corporate advisor to advance the development of BETR-001, the company's proprietary non-hallucinogenic derivative of LSD. Carcillo, a former professional hockey player who won two Stanley Cups with the Chicago Blackhawks, brings firsthand experience with traumatic brain injury after being forced to retire at age 30 due to Post Concussion Syndrome following seven concussions during his NHL career.
Following his retirement from professional hockey in 2015, Carcillo established a non-profit organization dedicated to assisting former NHL players suffering from post-concussion syndrome and mental health issues. His advocacy work expanded through his role as founder and CEO of Wesana Health, a life sciences company that explored psilocybin-based medicine for traumatic brain injury treatment. This background positions him uniquely to contribute to BetterLife's development efforts for neurological disorders.
Carcillo emphasized the significance of his new role, stating that joining BetterLife represents the natural next step in his mission to help concussion survivors. He highlighted the potential of BETR-001 to deliver psychedelic healing benefits without regulatory barriers, noting the importance of serotonergic benefits for those living with brain trauma. His personal experience with the invisible weight of concussion informs his commitment to advancing treatments that could help athletes, veterans, and others regain their quality of life.
Dr. Ahmad Doroudian, CEO of BetterLife, expressed enthusiasm about Carcillo's appointment, noting that his firsthand experience with traumatic brain injury and passion for advancing treatments will provide invaluable guidance. The collaboration aims to accelerate development of BETR-001, which is currently in preclinical and IND-enabling studies for conditions including traumatic brain injury, cluster headache, and migraine.
BetterLife's BETR-001 represents a significant advancement in neurological treatment development due to its non-hallucinogenic and non-controlled status, allowing for potential self-administration without the regulatory hurdles associated with traditional psychedelic compounds. The company holds a synthesis patent for BETR-001 that eliminates regulatory barriers and has pending patents for composition and method of use that could provide protection until approximately 2042. For additional information about the company's developments, visit https://www.blifepharma.com.
The appointment signals BetterLife's strategic focus on leveraging real-world experience in traumatic brain injury to guide clinical development. This approach could potentially accelerate the path to effective treatments for millions affected by concussion-related conditions worldwide. The combination of scientific innovation and lived experience positions the company to address significant unmet medical needs in neurological disorders while navigating the complex regulatory landscape of psychedelic-derived medicines.
Curated from NewMediaWire
